# NanoCellect Biomedical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nanocellect-biomedical

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.nanocellect.com
- Total disclosed funding: $47M
- Latest round: Series D (Aug 13, 2021)
- Investors on record: 10

## About

NanoCellect Biomedical develops innovative microfluidic cell sorting technologies that enhance research efficiency across various scientific fields, including stem cell research and genomics, ensuring high cell viability during sorting processes.Founded in 2009 in San Diego, US, NanoCellect Biomedical specializes in advanced cell sorting solutions. The company has raised a total of USD 20.00 mn in funding, with the latest round being Series D, led by Warburg Pincus on August 13, 2021. The founders include Jose Morachis, Nate Heintzman, Sunghwan Cho, William Alaynick, and Yu-Hwa Lo. Chris Neary currently serves as the CEO.NanoCellect Biomedical specializes in the development and provision of advanced microfluidic cell sorting technologies aimed at enhancing research across various fields, including stem cell research, plant biology, genomics, antibody discovery, cell line development, and gene editing. Their flagship products, such as the WOLF G2 Cell Sorter and VERLO Image-Guided Cell Sorter, utilize low-pressure microfluidic systems that operate at less than 2 psi, ensuring high cell viability and integrity during sorting. This technology allows for gentle handling of sensitive cell types, minimizing shear stress and ensuring clonal outgrowth without differentiation. The company primarily serves academic research institutions, biotechnology firms, and pharmaceutical companies seeking efficient and reliable cell sorting solutions. These products are marketed and sold globally, with significant customer bases in North America, Europe, and Asia.NanoCellect Biomedical generates revenue through direct sales of its cell sorting devices and associated consumables, including microfluidic cartridges and calibration beads. The company structures its transactions primarily through B2B channels, engaging directly with research labs and institutions, as well as establishing partnerships with distributors in various regions. Regular transactions may involve clients purchasing equipment such as the WOLF Cell Sorter, alongside essential consumables for ongoing operations, thereby creating a recurring revenue stream through repeat purchases. The firm’s pricing model reflects the advanced technology and research capabilities provided by its products, ensuring that clients gain access to high-quality tools essential for their scientific endeavors.In August 2021, NanoCellect Biomedical, Inc. raised USD 20.00 mn in Series D funding, with the proceeds aimed at supporting the launch of NanoCellect's second-generation WOLF G2 cell sorting system and investing in future product development. The company plans to expand its commercial go-to-market strategies to enhance its presence in existing and new markets, focusing on sectors that require sophisticated cell sorting technologies.

## Funding rounds

- Series D, Aug 13, 2021, $20M — Warburg Pincus, Casdin Capital, Vertical Venture Partners, Anzu Partners, Illumina Ventures, FusionX Ventures, Sagian Equity
- Series C, Feb 1, 2021, $15M — Agilent Technologies, Yonghua Capital, Vertical Venture Partners, Illumina Ventures, FusionX Ventures, Sagian Equity
- Series B, Nov 29, 2017, $10M — Agilent Technologies, Vertical Venture Partners, Genoa Ventures, Anzu Partners, Illumina Ventures, FusionX Ventures
- Series A, Jan 22, 2016, $1.8M — FusionX Ventures

## Investors

- FusionX Ventures (https://capitalatlas.ai/funds/fusionx-ventures) — Series A, Series B, Series C, Series D
- Agilent Technologies — Series B, Series C
- Vertical Venture Partners (https://capitalatlas.ai/funds/vertical-venture-partners) — Series B, Series C, Series D
- Genoa Ventures (https://capitalatlas.ai/funds/genoa-ventures) — Series B
- Anzu Partners (https://capitalatlas.ai/funds/anzu-partners) — Series B, Series D
- Illumina Ventures (https://capitalatlas.ai/funds/illumina-ventures) — Series B, Series C, Series D
- Yonghua Capital (https://capitalatlas.ai/funds/yonghua-capital) — Series C
- Sagian Equity (https://capitalatlas.ai/funds/sagian-equity) — Series C, Series D
- Warburg Pincus (https://capitalatlas.ai/funds/warburg-pincus) — Series D
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series D